China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief Technology Officer, effective immediately. With over 30 years of industrial experience, Dr. Berry brings a wealth of knowledge and expertise to Everest Medicines, particularly in advancing projects from the pre-clinical development phase to commercialization.
Dr. Berry’s Extensive Experience in Biopharmaceuticals
Dr. Berry’s extensive experience includes development, scale-up, and manufacturing of biopharmaceuticals. He possesses strong knowledge of international regulatory guidelines for Good Manufacturing Practices (GMP) and Chemistry, Manufacturing and Control (CMC). In his new role as Chief Technology Officer, Dr. Berry will oversee all CMC activities at Everest Medicines and will be responsible for the operations and management of the company’s manufacturing facility in Jiashan, Zhejiang. This state-of-the-art facility is designed to meet global and Chinese GMP standards, with an annual production capacity of 700 million doses of mRNA vaccines.
Dr. Berry’s Previous Roles and Contributions
Prior to joining Everest Medicines, Dr. Berry served as Chief Technical Operations Officer for global operations at Clover Biopharmaceuticals, Ltd. (Clover), where he was responsible for Clover’s global drug substance and drug product development and manufacturing. His leadership experience also includes positions at multiple U.S. and international biotech firms, such as Dynavax Technologies Corp., and Novartis Diagnostics. Dr. Berry has also served as a CMC consultant at BioTechLogic, Inc. His expertise spans across large and small molecule drug substance and drug product development, manufacturing, testing, and drug product supply chain management.-Fineline Info & Tech
